On Friday, Shares of Cabot Oil & Gas Corporation (NYSE:COG), lost -3.99% to $26.50.
Cabot Oil & Gas Corporation stated its financial and operating results for the second quarter of 2015. “Despite our planned decision to curtail Marcellus volumes in the second quarter due to the adverse price environment, Cabot still generated production growth and reduced unit costs year-over-year,” said Dan O. Dinges, Chairman, President and Chief Executive Officer. “Our top-tier Marcellus asset affords us the ability to reduce our gross production volumes by about 500 million cubic feet (Mmcf) per day and still report positive normalized results.”
Second Quarter 2015 Financial Results
Equivalent production in the second quarter of 2015 was 138.0 billion cubic feet equivalent (Bcfe), compriseing of 128.4 billion cubic feet (Bcf) of natural gas and 1.6 million barrels (Mmbbls) of liquids (crude oil/condensate/natural gas liquids). These figures represent enhances of 8 percent, 5 percent, and 68 percent, respectively, contrast to the second quarter of 2014.
Cabot Oil & Gas Corporation, an independent oil and gas company, develops, exploits, explores for, produces, and markets natural gas, oil, and natural gas liquids in the United States. The company primarily focuses on the Marcellus Shale in northeast Pennsylvania with about 200,000 net acres in the dry gas window of the play; and the Eagle Ford Shale in south Texas with about 89,000 net acres in the oil window of the play.
Shares of Genetic Technologies Limited (ADR) (NASDAQ:GENE), declined -1.75% to $3.36, during its last trading session.
Molecular diagnostics company Genetic Technologies Limited, declared that underpinned by a strong balance sheet, following the successful capital raise in March 2015, the Company has launched an initiative to reinvigorate the pathway to Peer Review Publication. Attaining such publications in medical journals will assist to strengthen the Company’s commercial position and accelerate reimbursement talk aboutions with private payers. In addition, the Company plans to conduct three U.S. clinical studies and is presently in the process of preparing for the presentation of recently accomplished scientific validation studies.
The Company had formerly conducted multiple scientific studies to develop and validate the first generation BREVAGen test in addition to created two health economic models to demonstrate potential cost savings and health benefits associated with the BREVAGen test. Importantly, due to the nature of the technology and the specific improvements incorporated in BREVAGenplus, the research under taken and published based on the original version of the test remains applicable to the new iteration.
Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of genetic tests for breast and ovarian cancer, bowel and uterine cancer, and prostate cancer; neurogenetic diagnostic assays; and gene testing for Epilepsy SCN1A gene related disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
